1. Pink Sheet

Millennium Withdraws Velcade Follicular Lymphoma sNDA, Citing Business Decision

 
• By The Pink Sheet Daily

The company will continue to evaluate bortezomib in follicular lymphoma subgroups as part of its larger development program for the first-in-class proteasome inhibitor.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Pink Sheet